This article recommends learning from the early ART scale-up era and prioritizing equity in the delivery of next-generation HIV care. Without urgent and coordinated action
across global health agencies, funders, originators, companies, generic manufacturers, access mechanisms (eg, Medicines Patent Pool), policy makers, national governments, implementation partners, and civil society, LMICs might face the inequities of the early ART era. Global health stakeholders need to act now to ensure timely and equitable access to the next frontier of HIV treatment. The global health community needs to act swiftly and cohesively to ensure that long-acting ART does not become an innovation that widens inequities, but instead, becomes a means to close them.